Ticker,Title,Link
ARQT,Arcutis Reports Positive Results For Integument Study Of Roflumilast Cream 0.05% In AD In Children ,8/28/2024 3:32:21 PM
ARQT,Arcutis surges 18% as Mizuho highlights growth of Zoryve,8/23/2024 5:36:10 PM
ARQT,Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference,8/22/2024 2:00:00 PM
ARQT,Wall Street Analysts Are Bullish on Top Healthcare Picks,8/15/2024 11:00:27 AM
ARQT,Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update,8/14/2024 10:00:00 PM
ARQT,Arcutis Biotherapeutics earnings preview: what to expect,8/13/2024 3:01:13 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/2/2024 10:00:00 PM
ARQT,"Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024",8/1/2024 10:00:00 PM
ARQT,Morgan Stanley Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT),7/30/2024 12:19:59 PM
ARQT,Arcutis Biotherapeutics Commercially Launches Zoryve Cream 0.15% For Atopic Dermatitis ,7/29/2024 2:01:18 PM
ARQT,7 Biotech Stocks to Keep on Your Clinical Radar,7/23/2024 6:57:01 PM
ARQT,Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL,7/22/2024 2:00:00 PM
ARQT,Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data,7/17/2024 5:48:19 PM
ARQT,Immutep Up as Combo Therapy Meets Carcinoma Study Goals,7/15/2024 9:57:55 PM
ARQT,Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings),7/10/2024 2:00:16 PM
ARQT,FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age,7/9/2024 10:53:01 PM
ARQT,The 7 Best Under $10 Stocks to Buy in July 2024,7/6/2024 12:00:00 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/3/2024 10:00:00 PM
ARQT,Biotech Stocks Facing FDA Decision In July 2024 ,6/28/2024 3:49:28 PM
ARQT,FDA Expands Argenx's Vyvgart Label to Treat Rare Disorder,6/24/2024 9:58:06 PM
ARQT,Avidity Up 33% on Rare Muscle Disease Study Results,6/13/2024 9:44:43 PM
ARQT,"Analysts Are Bullish on These Healthcare Stocks: LivaNova (LIVN), BridgeBio Pharma (BBIO)",6/12/2024 7:53:10 AM
ARQT,Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing...,6/10/2024 8:30:00 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),6/5/2024 10:00:00 PM
ARQT,Strong Buy Rating for Arcutis Biotherapeutics Amid Rising Zoryve Cream Prescriptions and Market Expansion Potential,6/4/2024 9:16:08 AM
ARQT,Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference,6/3/2024 2:00:00 PM
ARQT,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",5/25/2024 2:24:03 PM
ARQT,"Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers",5/17/2024 2:00:30 PM
ARQT,Arcutis Biotherapeutics surges 22% on Q1 beats,5/15/2024 3:45:04 PM
ARQT,Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update,5/14/2024 10:00:00 PM
ARQT,Arcutis Biotherapeutics Q1 2024 Earnings Preview,5/13/2024 9:35:40 PM
ARQT,Wall Street Analysts Are Bullish on Top Healthcare Picks,5/8/2024 8:10:43 AM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/3/2024 10:00:00 PM
ARQT,Buy Rating Reiterated for ARQT Amidst Strong Zoryve Performance and Market Resilience,4/30/2024 6:50:06 AM
ARQT,"Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024",4/29/2024 10:00:00 PM
ARQT,"Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)",4/22/2024 6:50:43 AM
ARQT,Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts,4/12/2024 2:00:54 PM
ARQT,Arcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFO ,4/10/2024 2:32:45 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),4/5/2024 10:00:00 PM
ARQT,Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference,3/28/2024 1:00:00 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), Arcutis Biotherapeutics (ARQT) and Axsome Therapeutics (AXSM)",3/27/2024 7:20:17 AM
ARQT,"Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)",3/19/2024 5:50:30 AM
ARQT,"Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)",3/13/2024 6:30:24 AM
ARQT,"EQT, Genie Energy And Other Big Stocks Moving Lower On Monday",3/11/2024 3:37:52 PM
ARQT,Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting,3/10/2024 9:00:00 PM
ARQT,New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction,3/9/2024 10:00:00 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/5/2024 10:00:00 PM
ARQT,Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares,3/4/2024 10:00:00 PM
ARQT,Arcutis to Present at the TD Cowen 44th Annual Health Care Conference,2/29/2024 11:00:33 PM
ARQT,Arcutis Announces Proposed Public Offering,2/28/2024 10:10:00 PM
ARQT,Arcutis Biotherapeutics (ARQT) Gets a Hold from JonesTrading,2/27/2024 11:25:23 PM
ARQT,Arcutis Biotherapeutics Q4 2023 Earnings Preview,2/26/2024 4:19:44 PM
ARQT,"Catalyst Watch: Nvidia phenomenon, Amazon to the Dow and Anheuser-Busch drama",2/23/2024 8:00:00 PM
ARQT,Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results,2/16/2024 2:00:00 PM
ARQT,Buy Rating for Arcutis Biotherapeutics: Strong Market Protection and Anticipated Legal Defense Amid Generic Competition,2/9/2024 6:18:11 AM
ARQT,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Walgreens Boots Alliance (WBA) and Twist Bioscience (TWST)",2/7/2024 3:20:14 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2/6/2024 10:00:00 PM
ARQT,"IFBD, BFRG and GHSI among pre-market losers",2/1/2024 1:29:22 PM
ARQT,Arcutis Biotherapeutics files for a $300M mixed securities shelf,1/31/2024 10:40:53 PM
ARQT,Maintaining a Hold: Arcutis Biotherapeutics’ Mixed Q4 Outlook and Zoryve Market Potential,1/29/2024 10:15:14 PM
ARQT,"GDRX, SSRM and EOLS are among after hour movers",1/26/2024 9:59:28 PM
ARQT,Buy Rating for Arcutis Biotherapeutics Amidst Strong Zoryve Foam Launch and Market Penetration Potential,1/24/2024 6:40:25 AM
ARQT,"Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday",1/23/2024 4:32:31 PM
ARQT,Goldman Sachs Reaffirms Their Hold Rating on Arcutis Biotherapeutics (ARQT),1/22/2024 11:45:24 PM
ARQT,"iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session",1/19/2024 11:38:45 AM
ARQT,Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program,1/14/2024 10:00:00 AM
ARQT,"Flexsteel Industries Posts Strong Preliminary Results, Joins Wipro, Sify Technologies And Other Big Stocks Moving Higher In Friday's Pre-Market Session",1/12/2024 10:58:20 AM
ARQT,Expert Outlook: Arcutis Biotherapeutics Through The Eyes Of 7 Analysts,1/3/2024 1:00:23 PM
ARQT,Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session,12/28/2023 7:07:18 PM
ARQT,Arcutis Biotherapeutics: Hold Rating Amidst Fluctuating Prescription Trends and New Patient Growth,12/19/2023 7:37:12 AM
ARQT,Arcutis Biotherapeutics’ Zoryve Launch: Balancing Market Potential Against Financial Challenges,12/18/2023 8:05:28 PM
ARQT,"FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older",12/15/2023 11:11:43 PM
ARQT,"Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP), eFFECTOR Therapeutics (EFTR) and Arcutis Biotherapeutics (ARQT)",12/13/2023 7:20:43 AM
ARQT,Hold Rating on Arcutis Biotherapeutics Amid Declining Prescription Trends,12/5/2023 7:28:13 AM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),12/2/2023 4:00:49 AM
ARQT,Biotech Stocks Facing FDA Decision In December 2023 ,11/30/2023 8:53:23 AM
ARQT,Arcutis Biotherapeutics: FDA To Review SNDA For Roflumilast Cream 0.15% ,11/29/2023 2:24:13 PM
ARQT,3 Biotech Stocks With Key Catalysts Coming in December,11/15/2023 6:26:19 PM
ARQT,"Hold Rating on Arcutis Biotherapeutics: Balancing Achievable Financial Covenants, Zoryve’s Prospective Growth and Persistent Financing Concerns",11/8/2023 5:57:53 AM
ARQT,Arcutis Biotherapeutics (ARQT) was downgraded to a Hold Rating at JonesTrading,11/7/2023 9:17:35 PM
ARQT,What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics,11/6/2023 2:00:12 PM
ARQT,Hold Rating on Arcutis Biotherapeutics Inc. Amid Encouraging Q3 Results and Promising Future Expansion Plans,11/3/2023 9:16:58 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/2/2023 9:00:00 PM
ARQT,Mizuho Securities Analyst Puts a Hold Rating on Arcutis Biotherapeutics Amid Zoryve’s Underperformance and Potential Debt Concerns,10/26/2023 9:03:02 AM
ARQT,Arcutis to Report Third Quarter 2023 Financial Results,10/25/2023 10:00:00 PM
ARQT,Nasdaq Down Over 1%; Autoliv Raises FY23 Sales Outlook,10/20/2023 8:42:37 PM
ARQT,Strong Financial Health and Progress in Product Development Bolster Buy Rating for Arcutis Biotherapeutics,10/19/2023 11:05:28 PM
ARQT,"Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023",10/13/2023 5:00:31 PM
ARQT,Positive Outlook for Arcutis Biotherapeutics: FDA Approvals and Potential Product Launches Drive Buy Rating,10/9/2023 2:27:12 PM
ARQT,Arcutis Receives FDA Approval For Its SNDA ZORYVE ,10/6/2023 8:27:24 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/5/2023 10:00:00 PM
ARQT,Boosted Confidence in Arcutis Biotherapeutics: Analyzing the Potential Impact of Leadership Changes and Upcoming Product Launch,9/29/2023 6:37:50 AM
ARQT,Arcutis Appoints L. Todd Edwards as Chief Commercial Officer,9/27/2023 2:00:00 PM
ARQT,"Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday",9/26/2023 4:49:40 PM
ARQT,Where Arcutis Biotherapeutics Stands With Analysts,9/25/2023 10:00:58 PM
ARQT,JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT),9/19/2023 10:35:09 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/15/2023 10:00:00 PM
ARQT,JonesTrading Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT),9/13/2023 8:35:05 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), MoonLake Immunotherapeutics (MLTX) and Arcutis Biotherapeutics (ARQT)",9/12/2023 3:50:38 PM
ARQT,US Stocks Mostly Higher; RH Posts Upbeat Earnings,9/8/2023 4:03:24 PM
ARQT,Arcutis Reports Results From INTEGUMENT-OLE Long-term Extension Trial Of Roflumilast Cream 0.15% ,9/7/2023 3:00:55 PM
ARQT,Arcutis to Present at Upcoming Investor Conference,9/5/2023 10:00:00 PM
ARQT,3 Biotech Stocks Due for a Massive Short Squeeze,8/31/2023 2:33:45 PM
ARQT,Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  ,8/29/2023 2:00:00 PM
ARQT,"Analysts’ Top Healthcare Picks: Arcutis Biotherapeutics (ARQT), Cytokinetics (CYTK)",8/25/2023 12:10:13 PM
ARQT,JonesTrading Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT),8/23/2023 3:25:23 PM
ARQT,Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session,8/21/2023 8:36:58 PM
ARQT,Arcutis Appoints Interim Chief Financial Officer (CFO),8/18/2023 10:30:00 PM
ARQT,7 Analysts Have This to Say About Arcutis Biotherapeutics,8/10/2023 8:00:38 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Deciphera Pharmaceuticals (DCPH) and Landos Biopharma (LABP)",8/9/2023 8:30:22 PM
ARQT,"Arcutis Biotherapeutics GAAP EPS of -$1.16 beats by $0.08, revenue of $5.2M beats by $0.58M",8/8/2023 8:15:23 PM
ARQT,Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities,8/4/2023 12:25:06 PM
ARQT,JonesTrading Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT),8/1/2023 3:55:04 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Zynex (ZYXI) and Arcutis Biotherapeutics (ARQT),7/28/2023 12:10:22 PM
ARQT,"3 Best Stocks to Buy Now, 7/20/2023, According to Top Analysts",7/20/2023 10:50:06 AM
ARQT,8 Analysts Have This to Say About Arcutis Biotherapeutics,7/18/2023 8:00:52 PM
ARQT,Wall Street Analysts Are Bullish on Top Healthcare Picks,7/17/2023 3:20:12 PM
ARQT,"CARA, VRM and TSP are among after hour movers",7/12/2023 9:31:16 PM
ARQT,Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities,7/7/2023 1:25:12 PM
ARQT,Arcutis up 15% on growth in prescriptions for Zoryve psoriasis cream,6/30/2023 5:49:46 PM
ARQT,"PRPL, GSIT and FARM are among after hour movers",6/28/2023 9:34:03 PM
ARQT,Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities,6/23/2023 12:45:26 PM
ARQT,"3 Best Stocks to Buy Now, 6/19/2023, According to Top Analysts",6/19/2023 11:36:54 AM
ARQT,"Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Stereotaxis (STXS)",6/16/2023 1:20:52 PM
ARQT,"ARCT, ENVX and XERS are among after hour movers",6/15/2023 9:38:38 PM
ARQT,Analyst Expectations for Arcutis Biotherapeutics's Future,6/12/2023 11:01:01 PM
ARQT,Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities,6/9/2023 12:35:06 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Arcutis Biotherapeutics (ARQT),6/2/2023 12:20:25 PM
ARQT,JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT),5/26/2023 4:25:27 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Sanofi (OtherSNYNF) and Arcutis Biotherapeutics (ARQT)",5/25/2023 1:40:11 AM
ARQT,Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT),5/19/2023 12:35:47 PM
ARQT,7 Short-Interest Stocks to Target for Explosive Gains,5/18/2023 8:37:15 PM
ARQT,The Latest Analyst Ratings for Arcutis Biotherapeutics,5/17/2023 10:01:43 PM
ARQT,Arcutis Biotherapeutics (ARQT) Receives a Buy from JonesTrading,5/11/2023 10:55:07 AM
ARQT,Arcutis down 20% on Q1 bottom and top line misses,5/10/2023 5:55:45 PM
ARQT,Arcutis Biotherapeutics reports Q1 results,5/9/2023 9:09:03 PM
ARQT,Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT),5/5/2023 12:36:00 PM
ARQT,"Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday",5/1/2023 9:33:51 AM
ARQT,Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN) and Arcutis Biotherapeutics (ARQT),4/28/2023 1:10:05 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Elevance Health (ELV) and Arcutis Biotherapeutics (ARQT)",4/21/2023 1:00:27 PM
ARQT,Arcutis stock pops on getting FDA review for skin disorder cream roflumilast,4/18/2023 12:54:20 PM
ARQT,Mizuho Securities Remains a Buy on Arcutis Biotherapeutics (ARQT),4/14/2023 4:05:14 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Arcutis Biotherapeutics (ARQT),4/7/2023 1:50:13 PM
ARQT,"Arcutis psoriasis therapy Zoryve gets coverage on national, regional plans",4/5/2023 3:05:28 PM
ARQT,Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT),3/31/2023 1:05:08 PM
ARQT,Where Arcutis Biotherapeutics Stands With Analysts,3/29/2023 8:00:47 PM
ARQT,Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT),3/24/2023 1:45:18 PM
ARQT,"Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Arcutis Biotherapeutics (ARQT)",3/16/2023 12:31:19 PM
ARQT,"Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Arcutis Biotherapeutics (ARQT)",3/15/2023 4:40:13 PM
ARQT,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)",3/14/2023 10:11:00 AM
ARQT,"Catalyst watch: Microsoft ramps up AI talk, FedEx earnings and voting drama with AMC Entertainment & Ritchie Bros.",3/10/2023 8:00:56 PM
ARQT,Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities,3/8/2023 8:55:04 PM
ARQT,JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT),3/2/2023 12:05:08 AM
ARQT,Needham Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT),3/1/2023 12:25:36 PM
ARQT,Arcutis Biotherapeutics Q4 results beat estimates,2/28/2023 10:10:57 PM
ARQT,Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT),2/21/2023 6:55:06 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Moderna (MRNA) and Bio-Rad Laboratories (BIO)",2/17/2023 1:20:28 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Arcutis Biotherapeutics (ARQT) and Genenta Science SpA Sponsored ADR (GNTA)",2/8/2023 5:50:06 PM
ARQT,Mizuho Securities Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT),2/3/2023 1:55:20 PM
ARQT,Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities,1/27/2023 2:05:12 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Concert Pharma (CNCE) and Arcutis Biotherapeutics (ARQT),1/20/2023 2:30:28 PM
ARQT,Arcutis up 9% as Cowen says to add to positions as shares are 'meaningfully discounted',1/19/2023 8:49:31 PM
ARQT,"Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months",1/17/2023 1:48:17 PM
ARQT,"SGMO, CDNS and HOLX are among after hour movers",1/13/2023 10:58:33 PM
ARQT,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcutis Biotherapeutics (ARQT), Landos Biopharma (LABP) and Theseus Pharmaceuticals (THRX)",1/6/2023 1:01:05 PM
ARQT,Mizuho Securities Remains a Buy on Arcutis Biotherapeutics (ARQT),12/30/2022 1:15:14 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Arcutis Biotherapeutics (ARQT),12/23/2022 12:50:11 PM
ARQT,JonesTrading Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT),12/20/2022 4:35:21 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Synlogic (SYBX) and Arcutis Biotherapeutics (ARQT),12/16/2022 12:50:15 PM
ARQT,"Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Arcutis Biotherapeutics (ARQT)",12/12/2022 6:11:45 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Arcutis Biotherapeutics (ARQT),12/9/2022 1:40:11 PM
ARQT,Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT),12/2/2022 12:25:06 AM
ARQT,MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis,12/1/2022 9:00:00 PM
ARQT,Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities,11/25/2022 1:35:06 PM
ARQT,"Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report",11/21/2022 3:15:00 PM
ARQT,"Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States",11/17/2022 2:00:00 PM
ARQT,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Idexx Laboratories (IDXX) and Arcutis Biotherapeutics (ARQT)",11/15/2022 4:40:52 PM
ARQT,Arcutis to Present at Upcoming Investor Conference,11/11/2022 2:00:00 PM
ARQT,JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT),11/10/2022 2:45:12 AM
ARQT,Needham Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT),11/9/2022 9:55:07 PM
ARQT,Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update,11/8/2022 10:02:00 PM
ARQT,"Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Nephros (NEPH)",11/4/2022 11:51:36 AM
ARQT,Mizuho Securities Remains a Buy on Arcutis Biotherapeutics (ARQT),10/28/2022 11:15:16 AM
ARQT,"Analysts’ Top Healthcare Picks: Plus Therapeutics (PSTV), Spectrum Pharmaceuticals (SPPI)",10/26/2022 1:50:30 PM
ARQT,Arcutis to Report Third Quarter Financial Results,10/25/2022 10:05:00 PM
ARQT,Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis,10/21/2022 2:00:00 PM
ARQT,Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Arcutis Biotherapeutics (ARQT),10/14/2022 12:01:28 PM
ARQT,Mizuho Securities Remains a Buy on Arcutis Biotherapeutics (ARQT),10/11/2022 8:45:30 AM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/5/2022 10:00:00 PM
ARQT,Mizuho Securities Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT),9/30/2022 8:06:30 PM
ARQT,"Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis",9/26/2022 5:02:42 PM
ARQT,Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities,9/23/2022 11:55:09 AM
ARQT,What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics,9/22/2022 5:17:46 PM
ARQT,JonesTrading Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT),9/21/2022 8:35:12 PM
ARQT,Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis,9/20/2022 5:07:40 PM
ARQT,"Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary",9/9/2022 11:47:11 PM
ARQT,Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics,9/8/2022 6:30:48 PM
ARQT,Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.,9/7/2022 11:00:00 PM
ARQT,New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress,9/6/2022 2:00:00 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/2/2022 10:00:00 PM
ARQT,Arcutis to Present at Upcoming Investor Conference,9/1/2022 2:00:00 PM
ARQT,"NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING",8/30/2022 4:00:00 PM
ARQT,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,8/24/2022 12:53:43 AM
ARQT,"Arcutis Concludes Dosing In Late-Stage Itchy Skin Study, Anticipates Regulatory Submission By Next Year",8/23/2022 3:17:03 PM
ARQT,Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients,8/22/2022 2:00:00 PM
ARQT,Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older,8/10/2022 3:00:00 PM
ARQT,Recap Of Thursday's Biotech Catalysts - End Of the Day Summary,8/5/2022 12:08:49 AM
ARQT,Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update,8/4/2022 10:01:00 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/3/2022 11:55:54 PM
ARQT,Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock,8/2/2022 10:02:00 PM
ARQT,"Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial",8/1/2022 3:03:05 PM
ARQT,Recap Of Friday's Biotech Catalysts - End of The Day Summary,7/29/2022 11:24:17 PM
ARQT,"Catalyst watch: Fed rate hike, new SPACs teed up and Amazon leads huge earnings rush",7/22/2022 7:00:34 PM
ARQT,7 Biotech Stocks to Buy for Q3,7/18/2022 10:00:31 PM
ARQT,Canada accepts Arcutis Biotherapeutics' new drug submission for its psoriasis skin cream,7/11/2022 3:10:47 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/5/2022 10:04:00 PM
ARQT,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,7/1/2022 11:26:23 AM
ARQT,Biotech Stocks Facing FDA Decision In July 2022 ,6/28/2022 9:17:30 AM
ARQT,Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis,6/6/2022 1:30:00 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),6/3/2022 10:16:00 PM
ARQT,Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock,5/26/2022 7:26:47 PM
ARQT,50 Stocks Moving In Wednesday's Mid-Day Session,5/25/2022 6:10:38 PM
ARQT,Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update,5/5/2022 10:01:00 PM
ARQT,Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis,4/6/2022 2:00:00 PM
ARQT,Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts,3/28/2022 2:00:00 PM
ARQT,Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting,3/25/2022 12:30:00 PM
ARQT,National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments,3/22/2022 1:00:00 PM
ARQT,Arcutis to Host Investor Day on March 28,3/21/2022 1:00:00 PM
ARQT,Arcutis Biotherapeutics initiated with a buy on Goldman Sachs; sees 163% upside,3/18/2022 2:53:32 PM
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/14/2022 9:05:00 PM
ARQT,Arcutis to Present at Upcoming Investor Conference,3/2/2022 11:30:00 AM
ARQT,Arcutis Biotherapeutics GAAP EPS of -$1.42 beats by $0.18,2/22/2022 10:25:16 PM
ARQT,Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis,2/1/2022 2:00:00 PM
ARQT,Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast,12/23/2021 4:17:58 PM
ARQT,FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis,12/22/2021 10:01:00 PM
ARQT,Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary,12/16/2021 2:00:00 PM
ARQT,Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream,12/13/2021 2:00:00 PM
ARQT,Arcutis to Present at Upcoming Investor Conference,11/10/2021 2:02:00 PM
ARQT,Arcutis Biotherapeutics EPS beats by $0.11,11/4/2021 9:17:58 PM
ARQT,Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis,10/4/2021 2:00:00 PM
ARQT,New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress,9/30/2021 2:30:00 PM
ARQT,Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent,9/28/2021 10:05:00 PM
ARQT,New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress,9/27/2021 2:05:00 PM
ARQT,Arcutis to Present at Upcoming Investor Conferences,9/9/2021 10:10:00 PM
ARQT,Arcutis Announces Appointment of Keith Leonard to Board of Directors,9/2/2021 10:10:00 PM
ARQT,Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis,8/25/2021 2:00:00 PM
ARQT,Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update,8/5/2021 10:05:00 PM
ARQT,Arcutis Announces Additions to its Investor Relations and Communications Team,8/2/2021 10:05:00 PM
ARQT,Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis,7/21/2021 2:00:00 PM
ARQT,Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis,7/12/2021 2:00:00 PM
ARQT,Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study,7/1/2021 5:17:29 PM
ARQT,"Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021",6/30/2021 4:16:19 PM
ARQT,Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies,6/23/2021 2:00:00 PM
ARQT,Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors,6/9/2021 10:01:00 PM
ARQT,Rajvir Madan Joins Arcutis as Chief Digital and Information Officer,6/1/2021 1:30:00 PM
ARQT,"Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021",5/27/2021 4:02:07 PM
ARQT,Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium,5/3/2021 10:09:23 PM
ARQT,38 Stocks Moving In Friday's Mid-Day Session,4/30/2021 6:11:34 PM
ARQT,"Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation",4/23/2021 5:05:14 PM
ARQT,Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX),4/19/2021 3:05:00 PM
ARQT,Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years,4/12/2021 3:05:00 PM
ARQT,Arcutis appoints new CFO,3/26/2021 5:05:51 PM
ARQT,Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo,3/18/2021 2:05:00 PM
ARQT,"Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring...",3/17/2021 9:05:00 PM
ARQT,Arcutis to Present at the Cowen 41st Annual Health Care Conference,2/25/2021 11:15:00 PM
ARQT,Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff,2/18/2021 3:00:00 PM
ARQT,Arcutis Biotherapeutics Raises $192.5 Million In Upsized Offering,2/3/2021 12:57:18 PM
ARQT,"The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment",2/2/2021 2:05:48 PM
ARQT,70 Stocks Moving In Monday's Mid-Day Session,2/1/2021 7:29:07 PM
ARQT,Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis,1/20/2021 3:00:00 PM
ARQT,Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis ,1/13/2021 3:00:00 PM
ARQT,Matthew Moore Joins Arcutis as Chief Business Officer ,1/11/2021 3:00:00 PM
ARQT,"Marinus Pharmaceuticals, Provention Bio take spot in Nasdaq Biotechnology Index",12/21/2020 8:56:36 PM
ARQT,"Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020",12/9/2020 3:00:00 PM
ARQT,Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for...,12/7/2020 3:00:00 PM
ARQT,"Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020",12/2/2020 10:05:00 PM
ARQT,Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis,12/1/2020 10:05:00 PM
ARQT,"AZN's COVID Shot 70% Effective On Average, ARQT Aces Scalp Psoriasis Study, BLRX' BLAST Fizzles ",11/24/2020 7:55:02 AM
ARQT,Arcutis Bio soars 17% on promising roflumilast foam data for scalp and body psoriasis,11/23/2020 2:03:03 PM
ARQT,Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference,11/11/2020 10:05:00 PM
ARQT,Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update,11/5/2020 10:05:00 PM
ARQT,Arcutis Announces Appointment of Terrie Curran to Board of Directors,11/4/2020 10:05:00 PM
ARQT,Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis,11/2/2020 3:00:00 PM
ARQT,Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences,10/30/2020 2:07:04 AM
ARQT,Arcutis Completes Enrollment in Phase 1/2b Study Evaluating  ARQ-252 in Chronic Hand Eczema,10/26/2020 2:00:10 PM
ARQT,Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent  Private Placement of Common Stock,10/6/2020 10:05:10 PM
ARQT,Stock Alert: Arcutis Biotherapeutics Falls 15% ,10/2/2020 3:56:50 PM
ARQT,Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock,9/29/2020 10:51:15 PM
ARQT,Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis,9/16/2020 3:00:10 PM
ARQT,Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020,9/15/2020 3:00:10 PM
ARQT,Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA ,9/8/2020 3:00:10 PM
ARQT,Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update,8/11/2020 10:02:10 PM
ARQT,Arcutis to Present at the Wedbush PacGrow Healthcare Conference,8/10/2020 3:00:10 PM
ARQT,Bethany Dudek Joins Arcutis as Vice President of Quality ,8/4/2020 3:00:10 PM
ARQT,The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis,8/3/2020 3:00:10 PM
ARQT,Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis,7/31/2020 3:00:10 PM
ARQT,"Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer",7/27/2020 3:00:10 PM
ARQT,Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating  ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis,7/20/2020 3:00:10 PM
ARQT,The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis,7/15/2020 11:07:02 PM
ARQT,Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema,7/13/2020 3:00:10 PM
ARQT,Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis,6/22/2020 3:00:10 PM
ARQT,Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference,6/10/2020 10:05:10 PM
ARQT,Ayisha Jeter Joins Arcutis as Vice President of Market Access ,6/1/2020 3:00:10 PM
ARQT,Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations,5/27/2020 3:00:10 PM
ARQT,Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update,5/12/2020 10:05:10 PM
ARQT,Halley E. Gilbert Appointed to Arcutis Board of Directors,4/27/2020 2:30:10 PM
ARQT,Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema,4/21/2020 3:00:10 PM
ARQT,Kimberly Lathroum Joins Arcutis as Vice President of Marketing,3/23/2020 1:30:00 PM
ARQT,Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis,3/16/2020 1:37:35 PM
ARQT,Key events next week - healthcare,3/13/2020 3:08:38 PM
ARQT,Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications,3/5/2020 2:30:00 PM
ARQT,Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology...,3/3/2020 2:30:00 PM
ARQT,Arcutis to Present at the Cowen 40th Annual Health Care Conference,2/19/2020 2:30:00 PM
ARQT,Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis,2/13/2020 2:30:00 PM
ARQT,Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,2/4/2020 10:05:00 PM
